Try our Advanced Search for more refined results
Health - May, 2010
200 articles
- 3rd Circ. Revives Suit Tying PwC To Hospital Fraud
- High Court Urged Not To Hear ERISA Preemption Case
- Teva To Close Down Maligned Sedative Propofol
- Judge OKs Class In Dendreon Securities Suit
- Costco Settles Tylenol Infant Death Suit
- Novartis Caught In Aredia, Zometa Ad Fib
- Cephalon Faces Another Provigil Pay-For-Delay Suit
- St. Jude Sues BSC To Block Noncompete Agreement
- Solvay Loses Bid To Transfer Sales Rep's FLSA Suit
- Investors Appeal Dismissal Of BSC Stent Fraud Case
- Fed. Circ. Won't Revisit Decision To Nix Applera IP Win
- Actavis To Pay $1.2M In Idaho AWP Case
- St. Vincent's Attys' Retainer Requests Face Scrutiny
- Howmedica, Wright End Knee Implant Patent Spat
- False Dietary Supplement Ads A Problem: FTC
- Hospital's Suit Over Wash. Angioplasty Rules Nixed
- USPTO Affirms Abbott Protein Patent In War With Yeda
- Teva, Teenage Girl Settle Acne Drug Blindness Suit
- FDA Crime Unit To Investigate Tylenol Recalls
- Canadian Competition And Foreign Investment Issues
- Teva Resolves Glaxo IP Suit Over Generic Combivir
- Impax Loses Bid To Toss MDL Over Generic Wellbutrin
- Celgene, Barr Resolve Spat Over Generic Thalomid
- Wyeth Seeks $1.3M In Wholesaler Recall Refund Spat
- Novartis Trial Holds Key Lessons For Attorneys
- FDA Requires Liver Risk Warning On Alli, Xenical
- Heartburn Meds Could Up Risk Of Fractures: FDA
- FDA Still Seeks Link Between J&J Recall, Complaints
- FTC Urges 2nd Circ. To Overturn Tamoxifen Precedent
- Fried Frank Reps New Mountain In $280M Covidien Deal
- Senate Bill Would Boost Dietary Supplement Oversight
- Feingold Pushes For Drug Imports, Price Negotiations
- Digitek MDL Plaintiffs Lose Class Certification Bid
- Antitrust Counts Nixed In Inmate Medical Services Suit
- Fee Disputes Erupt In Saint Vincent's Bankruptcy
- FDA Warns J&J Unit Over Faulty Sterilization Tools
- Life Tech Sues Illumina Over DNA Device Patents
- CareGroup Pays $8.5M To Settle FLSA, ERISA Suit
- NH Still Trying To Nab $110M Surplus: Malpractice Fund
- Baxter Faces New Suit Over Quaid Twins' Overdose
- Class Action Over $28.1B Novartis, Alcon Deal Axed
- Ropes & Gray Adds Jones Day Atty To Antitrust Ranks
- Genzyme Takes Shot At Watson Over Renvela ANDA
- How FDA Disclosure Proposals Would Affect Industry
- Harkin Questions FDA In Wake Of J&J Drug Recall
- Genzyme Goes After Sandoz Again Over Hectorol
- Takeda Sues Dr. Reddy's Over Generic Actos
- Retractable Wins $5M Syringe Patent Suit V. Becton
- Varney Vows Tough Reviews For Health Insurer Mergers
- Greenberg Traurig Reps Gentiva In $1B Merger
- CMS Offers Temporary Fix For Medicare 'Donut Hole'
- High Court Seeks SG's Input On Generic-Drug Liability
- Barr Squashes Fluoxetine Stabbing Death Suit
- Wyeth Sued For Off-Label Rapamune Sales
- 7th Circ. Revives Chicago Paramedics' FLSA Suit
- Genzyme To Pay $175M Over Drug Safety Violations
- Suit Says Merck Leaked Trade Secrets To IBM
- Counterclaims Dropped In Merck-Sandoz Patent Suit
- Quality Initiatives In Health Care Reform
- En Banc Rehearing Denied Over OxyContin Potency
- Whistleblowing MD Gets $23.5M In Kickbacks Deal
- Mylan's Antitrust Claims Nixed In Prilosec IP Suit
- AstraZeneca Seeks Stay Of Dr. Reddy's Fees Award
- Abbott To Buy Piramal Generics Unit For $3.7B
- Viagra Use Linked To Long-Term Hearing Loss
- New Developments Regarding Calif. Prop 64
- India, Brazil Fight Dutch Generic Drug Seizures At WTO
- Widower Hits Pfizer With Lyrica Negligence Suit
- Consumer Groups Urge 2nd Circ. To Rehear Cipro Case
- German Court Revokes GSK's Advair Patent
- Schering Wins Neutrogena Sunscreen False Ad Suit
- Brazil Clears Sanofi's $635M Medley Pharma Buy
- The FDA 'Bad Ad' Program — Us Vs. Them
- Amedisys Revives Claims Against National Century
- Braintree Loses Bid To Toss MiraLax Antitrust Suit
- King Loses Injunction Bid In Skelaxin Suit V. Sandoz
- Akin Gump Snags Jones Day Partner
- Nationwide Fixed-Pay Insurance Settlement OK'd
- Aerocrine Resolves Apieron Patent Claims In Asset Buy
- Digital Health Liability: We Are Not In Kansas Anymore!
- Ex-McKesson Chairman To Pay $2M In SEC Deal
- Novartis Slapped With $250M Verdict In Sex Bias Case
- TLC Vision Plan Approval Sparks Outcry From MMA
- Applied Fights Off Injunction But Not $4.8M Verdict
- FDA Expands Probe Into J&J Unit Tied To Recall
- France Nixes Teva Unit's Relief Bid In Plavix Case
- Dental Group's RICO Action Against Insurers Squashed
- Calif. Plaintiffs Appeal Pay-For-Delay Cipro Case
- HUD-Insured Financing For Long-Term Care Facilities
- Sagent Recalls Anti-Infection Drug Over Contamination
- $285M Will Hit Novartis 'Where It Hurts': Plaintiffs
- China Fines Simcere Unit $3.7M Over Rabies Vaccines
- AstraZeneca, Teva Reach Patent Deal Over Entocort
- Siemens Denied Patent Rehearing In Enzo DNA Spat
- Mylan Generic Infringes Sanofi's Uroxatral Patent: Judge
- 115 Calif. Suits Cut From Prempro MDL
- Cravath Reps Universal Health In $3B Psychiatric Deal
- Weil Reps Equity Firm In $294M Radiology Co. Purchase
- States Join Suit Alleging J&J Kickbacks To Omnicare
- Jury Hits Novartis With $3.4M Sex Bias Verdict
- Stryker Wins Dismissal Of Suit Over Hip Implant
- Skadden, MoFo Help Secure $4B OSI, Astellas Deal
- Fed. Circ. Shoots Down Vaccine-Autism Link Appeal
- When Is A Win A Win With Attorneys' Fees?
- Fed. Circ. Revives Cochlear Implant Patent Dispute
- Shire Takes Shot At Actavis Over Intuniv ANDA
- GE Healthcare Recalls Anesthesia Devices: FDA
- Medicis Mulls New Solodyn IP Suit Against Mylan
- Damages Claim Upheld In Gore Faulty Device Suit
- Okla. Jury Slams Allergan With $15M Botox Verdict
- Aetna Wants To Rep End Payers In Wellbutrin MDL
- Takeda Settles Diabetes Drug Patent Dispute
- Walgreen Halts Genetic Test Kit Sale Post-FDA Warning
- FDA Warns Against Swallowing Benadryl Itch Gel
- A Blow To Gene Patenting: Impact On Innovators
- Plaintiffs Firms Wage Battle Over Fees In Vioxx MDL
- NYC's Bid To Undo Health Insurance Merger Nixed
- White House Defends Insurance Mandate In Court
- Novozymes Sues Danisco Over New Enzyme Patent
- St. Vincent's Monitor Offers Plan For Malpractice Claims
- King Wins Preliminary Injunction In Skelaxin Battle
- Express Scripts' Prices Not Set In Bad Faith: 11th Circ.
- Howmedica Off Hook In Faulty Knee Replacement Suit
- Anti-Fraud Provisions In The New Health Care Law
- Pfizer Hit With Securities Suit Over Bextra Marketing
- Genzyme Board Probing Insider Stock Sales
- FDA Urges Doctors To Report Illegal Drug Pitches
- Fed. Circ. Backs IP Extension For Photocure's Metvixia
- Childhood Obesity Task Force Unveils Action Plan
- Bias Plaintiffs' Atty Says Novartis Expert Cooked Stats
- GSK To Pay $60M To Settle Avandia Suits
- Lender Squeeze, Loan Defaults Push Chem Rx To Ch. 11
- FLSA Action Takes Aim At Gentiva's Wage Plan
- Fed. Circ. Affirms Patent Extension For Levaquin
- Discovery To Buy UK's Standard Life For $209M
- Canada's New Process For Approval Of Biosimilar Drugs
- Paul Hastings Reps Korean Drug Co. In $126M GSK Deal
- Tyco Resolves Kimberly-Clark Breathing Tube IP Suit
- Immutopics Didn't Infringe Antibody Patent: Fed. Circ.
- Novartis Fingers 'Rogue Male' Workers In Closing Args.
- Merck, Glenmark Avoid Trial With Zetia Patent Deal
- 11th Circ. Affirms Expert Exclusion In Accutane Suits
- 17 More States Want In On Wyeth Medicaid Suits
- Nexium Deceptive Marketing Action Tossed
- DNA Patent In Monsanto Suit Upheld On Re-Exam
- Micro Health Latest To Settle Mannatech's Patent Suit
- Costco Experts Nixed In Tylenol Infant Death Case
- Bill Would Screen More Chemicals In Drinking Water
- A Road Map To The Electronic Health Records Program
- Teva, Baxter Hit With $500M Damages In Hepatitis Case
- Watson Gets License From Teva As Part Of Settlement
- Divided Fed. Circ. Nixes Rehearing Of Mirapex Spat
- Drug Mart Tallman, Purdue Settle In OxyContin MDL
- Feinstein Calls For Inquiry Into Anthem Rate Hike Errors
- TLC Vision Wins Confirmation Of Ch. 11 Plan
- Simpson Thatcher To Help HCA Go Public Again
- 'DNA: Not Patentable Subject Matter' — Counterpoint
- Medicis, Ranbaxy Forge Pact For Solodyn Generic
- Utah Sues Over Off-Label Seroquel, Risperdal
- Plaintiffs Renew Schering Off-Label Marketing Claims
- Novartis Sex Bias Plaintiffs Draw Ire Over Witness
- USPTO Bearing Down On Backlog: Deputy Director
- Skadden Advises Endo On $223M HealthTronics Deal
- Health Partners, Medica Drop OxyContin Antitrust Suit
- Lilly Redoubles Fight Against Watson Evista Generic
- Xenomics, Sequenom To Arbitrate $300M Contract Spat
- House Panel To Probe Children's Tylenol Recall
- Covidien's Restoril Dose Patent Deemed Obvious
- Legislating Break Time For Nursing Mothers
- Dr. Reddy's Prilosec Fees Bid Sends Judge Reeling
- Novartis Nears End Of Its Case In Sex Bias Trial
- Merck Prevails In Bellwether Fosamax Case
- ERISA Action Against Baxter Tossed Out
- Leahy Revives Insurance Antitrust Exemption Repeal
- $5B Early Retirement Program Gets Early Start
- Weil, Wilson Advise On $213M Bard, SenoRx Merger
- Qui Tam Kickback Suit Against Stryker Booted
- J&J Plant Halts Production After FDA Finds Bacteria
- Lilly Targets Watson Over Osteoporosis Drug ANDA
- Nestle, Alcon Shareholders Reach Deal In Merger Suit
- MMSEA Reporting And Reimbursement Requirements
- DOJ Hits St. Jude With Demand Over Defibrillators
- Off-Label Marketing Suit Costs Novartis $72M
- Wyeth Drums For New Prempro Trial After $58M Hit
- FDA To Probe Prostate Cancer Drug Class
- HHS Backs 'High-Risk' Pools Despite Opposition
- Baxter Told To Recall, Destroy 200K Infusion Pumps
- Wyeth's Bid To Extend Cattle Drug Patent Trampled
- Greenberg Escapes Surgeons' $10M Malpractice Suit
- Hospital Co. Hit With Class Action Over Meal Breaks
- USPTO Panel Rejects Human Stem Cell Patent
- Ill. Toughens Up Whistleblower Protection Act
- AstraZeneca Initiates 9 IP Suits Over Crestor ANDAs
- High Court Rebuffs Bayer Bid To Revive Yasmin Patent
- J&J Unit Recalls Children's Tylenol, Other Drugs
- CVS Asst. Managers Seek Conditional Cert. In OT Suit
- America Service Settles Stock Fraud Action For $15M
- Pfizer Fails To Bar Evidence In Neurontin Suicide Suit
- High Court Won't Hear Pfizer Shareholder Suit
- 3 Myths Of In-House Attorney-Client Privilege